Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
life sciences
national blog main
san francisco blog main
san francisco top stories
3
×
boston top stories
deals
national top stories
san francisco
startups
alphabet
azacitidine
beta-thalassemia
boston
broad institute of harvard and mit
brook byers
cancer diagnostics
charles chu
crispr
crispr cas14
dacogen
decheng capital
decitabine
diagnostic
dna
epigenetics
epizyme
farydak
flagship pioneering
freenome
fulcrum therapeutics
google
grail
guardant health
infectious disease
insulated genomic domains
investing
kaleido biosciences
kleiner perkins
What
based
3
×
developing
aims
announced
approach
area
available
bay
big
bio
biopsy
biosciences
biotech
blood
buildout
called
cancer
cas
cheaper
close
company
crispr
debuts
develop
diagnostics
drugs
epigenetic
epigenetics
expects
faster
field
firm
flagship’s
genomic
liquid
lucence
mammoth
medicine
medicines
morning
Language
unset
3
×
Current search:
based
×
unset
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further